Report date: Apr 23, 2024
Conflict count: 350216
Publisher: American Society of Hematology
Title count: 2
Conflict count: 14369


==========================================================

Created: 2019-10-10 05:11:18.0
ConfID: 5529549
CauseID: 1455911883
OtherID: 27712014, 1455911883
JT: Hematology
MD: Kantarjian, 2000 ,1,90,2000,Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies
DOI: 10.1182/asheducation-2000.1.90(Journal) (5529549-N )
DOI: 10.1182/asheducation.V2000.1.90.90(Journal)
==========================================================

Created: 2019-10-10 08:12:35.0
ConfID: 5529550
CauseID: 1455923058
OtherID: 27712014, 1455923058
JT: Hematology
MD: Zaia, 2000 ,1,339,2000,Status of Cytomegalovirus Prevention and Treatment in 2000
DOI: 10.1182/asheducation-2000.1.339(Journal) (5529550-N )
DOI: 10.1182/asheducation.V2000.1.339.339(Journal)
==========================================================

Created: 2019-10-10 05:07:46.0
ConfID: 5529551
CauseID: 1455911257
OtherID: 27712014, 1455911257
JT: Hematology
MD: Williams, 2000 ,1,376,2000,Gene Therapy 2000
DOI: 10.1182/asheducation-2000.1.376(Journal) (5529551-N )
DOI: 10.1182/asheducation.V2000.1.376.376(Journal)
==========================================================

Created: 2019-10-10 05:38:07.0
ConfID: 5529552
CauseID: 1455914288
OtherID: 27712014, 1455914288
JT: Hematology
MD: Pearson, 2000 ,1,51,2000,A Polycythemia Vera Update: Diagnosis, Pathobiology, and Treatment
DOI: 10.1182/asheducation-2000.1.51(Journal) (5529552-N )
DOI: 10.1182/asheducation.V2000.1.51.51(Journal)
==========================================================

Created: 2019-10-10 06:56:36.0
ConfID: 5529554
CauseID: 1455918073
OtherID: 27712014, 1455918073
JT: Hematology
MD: McArthur, 2000 ,1,457,2000,Morphology Glossary
DOI: 10.1182/asheducation-2000.1.457(Journal) (5529554-N )
DOI: 10.1182/asheducation.V2000.1.457.457(Journal)
==========================================================

Created: 2019-10-10 12:45:09.0
ConfID: 5529555
CauseID: 1455943653
OtherID: 27712014, 1455943653
JT: Hematology
MD: Macintyre, 2000 ,1,180,2000,Non-Hodgkin''s Lymphoma: Molecular Features of B Cell Lymphoma
DOI: 10.1182/asheducation-2000.1.180(Journal) (5529555-N )
DOI: 10.1182/asheducation.V2000.1.180.180(Journal)
==========================================================

Created: 2019-10-10 04:23:36.0
ConfID: 5529556
CauseID: 1455907939
OtherID: 442504154
JT: Hematology
MD: Natkunam, 2007 ,1,210,2007,The Biology of the Germinal Center
DOI: 10.1182/asheducation-2007.1.210(Journal) (5529556-N )
DOI: 10.1182/asheducation.V2007.1.210.0010210(Journal)
==========================================================

Created: 2019-10-10 04:23:41.0
ConfID: 5529557
CauseID: 1455907942
OtherID: 442504154
JT: Hematology
MD: Reiter, 2007 ,1,285,2007,Diagnosis and Treatment of Childhood Non-Hodgkin Lymphoma
DOI: 10.1182/asheducation-2007.1.285(Journal) (5529557-N )
DOI: 10.1182/asheducation.V2007.1.285.0010285(Journal)
==========================================================

Created: 2019-10-10 05:19:04.0
ConfID: 5529558
CauseID: 1455912460
OtherID: 27712014, 1455912460
JT: Hematology
MD: Bussel, 2000 ,1,222,2000,Platelets: New Understanding of Platelet Glycoproteins and Their Role in Disease
DOI: 10.1182/asheducation-2000.1.222(Journal) (5529558-N )
DOI: 10.1182/asheducation.V2000.1.222.222(Journal)
==========================================================

Created: 2019-10-10 04:29:11.0
ConfID: 5529559
CauseID: 1455908187
OtherID: 1398847739
JT: Hematology
MD: Heuser, 2016 ,1,24,2016,Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?
DOI: 10.1182/asheducation-2016.1.24(Journal) (5529559-N )
DOI: 10.1182/asheducation.V2016.1.24.088333(Journal)
==========================================================

Created: 2019-10-10 09:53:17.0
ConfID: 5529560
CauseID: 1455930599
OtherID: 27712014, 1455930599
JT: Hematology
MD: Waldmann, 2000 ,1,394,2000,Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy
DOI: 10.1182/asheducation-2000.1.394(Journal) (5529560-N )
DOI: 10.1182/asheducation.V2000.1.394.394(Journal)
==========================================================

Created: 2019-10-10 07:59:35.0
ConfID: 5529561
CauseID: 1455922174
OtherID: 27712014, 1455922174
JT: Hematology
MD: Brenner, 2000 ,1,356,2000,Transfusion Medicine: New Clinical Applications of Cellular Immunotherapy
DOI: 10.1182/asheducation-2000.1.356(Journal) (5529561-N )
DOI: 10.1182/asheducation.V2000.1.356.356(Journal)
==========================================================

Created: 2019-10-10 05:49:06.0
ConfID: 5529562
CauseID: 1455914778
OtherID: 27712014, 1455914778
JT: Hematology
MD: Sullivan, 2000 ,1,319,2000,Bone Marrow Transplantation for Non-Malignant Disease
DOI: 10.1182/asheducation-2000.1.319(Journal) (5529562-N )
DOI: 10.1182/asheducation.V2000.1.319.319(Journal)
==========================================================

Created: 2019-10-10 04:49:35.0
ConfID: 5529564
CauseID: 1455909112
OtherID: 1396514514
JT: Hematology
MD: Young, 2015 ,1,111,2015,Anticoagulants in children and adolescents
DOI: 10.1182/asheducation-2015.1.111(Journal) (5529564-N )
DOI: 10.1182/asheducation.V2015.1.111.3917444(Journal)
==========================================================

Created: 2019-10-10 04:50:15.0
ConfID: 5529565
CauseID: 1455909136
OtherID: 36577089
JT: Hematology
MD: Storb, 2003 ,1,372,2003,Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors
DOI: 10.1182/asheducation-2003.1.372(Journal) (5529565-N )
DOI: 10.1182/asheducation.V2003.1.372.0010372(Journal)
==========================================================

Created: 2019-10-10 04:52:12.0
ConfID: 5529566
CauseID: 1455909226
OtherID: 974344208
JT: Hematology
MD: Ataga, 2009 ,1,54,2009,Novel therapies in sickle cell disease
DOI: 10.1182/asheducation-2009.1.54(Journal) (5529566-N )
DOI: 10.1182/asheducation.V2009.1.54.0010054(Journal)
==========================================================

Created: 2019-10-10 04:54:16.0
ConfID: 5529567
CauseID: 1455909329
OtherID: 1363082169
JT: Hematology
MD: Gotlib, 2013 ,1,529,2013,JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside
DOI: 10.1182/asheducation-2013.1.529(Journal) (5529567-N )
DOI: 10.1182/asheducation.V2013.1.529.3847112(Journal)
==========================================================

Created: 2019-10-10 04:55:12.0
ConfID: 5529568
CauseID: 1455909421
OtherID: 974344208
JT: Hematology
MD: Field, 2009 ,1,45,2009,Asthma and sickle cell disease: two distinct diseases or part of the same process?
DOI: 10.1182/asheducation-2009.1.45(Journal) (5529568-N )
DOI: 10.1182/asheducation.V2009.1.45.0010045(Journal)
==========================================================

Created: 2019-10-10 05:47:56.0
ConfID: 5529580
CauseID: 1455914712
OtherID: 27712014, 1455914712
JT: Hematology
MD: Franchini, 2000 ,1,409,2000,Viral Disease in Hematology
DOI: 10.1182/asheducation-2000.1.409(Journal) (5529580-N )
DOI: 10.1182/asheducation.V2000.1.409.409(Journal)
==========================================================

Created: 2019-10-10 05:08:03.0
ConfID: 5529581
CauseID: 1455911267
OtherID: 1374682252
JT: Hematology
MD: Alexander, 2014 ,1,181,2014,Clinically defining and managing high-risk pediatric patients with acute lymphoblastic leukemia
DOI: 10.1182/asheducation-2014.1.181(Journal) (5529581-N )
DOI: 10.1182/asheducation.V2014.1.181.3882466(Journal)
==========================================================

Created: 2019-10-10 05:08:14.0
ConfID: 5529582
CauseID: 1455911278
OtherID: 1363082169
JT: Hematology
MD: Artz, 2013 ,1,70,2013,Older patients/older donors: choosing wisely
DOI: 10.1182/asheducation-2013.1.70(Journal) (5529582-N )
DOI: 10.1182/asheducation.V2013.1.70.3850587(Journal)
==========================================================

Created: 2019-10-10 05:09:15.0
ConfID: 5529583
CauseID: 1455911528
OtherID: 1351047748
JT: Hematology
MD: Anderson, 2011 ,1,184,2011,New Insights into Therapeutic Targets in Myeloma
DOI: 10.1182/asheducation-2011.1.184(Journal) (5529583-N )
DOI: 10.1182/asheducation.V2011.1.184.3718203(Journal)
==========================================================

Created: 2019-10-10 05:09:40.0
ConfID: 5529584
CauseID: 1455911590
OtherID: 299666112
JT: Hematology
MD: Brissot, 2006 ,1,36,2006,Current Approaches to the Management of Hemochromatosis
DOI: 10.1182/asheducation-2006.1.36(Journal) (5529584-N )
DOI: 10.1182/asheducation.V2006.1.36.0010036(Journal)
==========================================================

Created: 2019-10-10 05:39:28.0
ConfID: 5529585
CauseID: 1455914334
OtherID: 27712014, 1455914334
JT: Hematology
MD: Gorin, 2000 ,1,69,2000,New Developments in the Therapy of Acute Myelocytic Leukemia
DOI: 10.1182/asheducation-2000.1.69(Journal) (5529585-N )
DOI: 10.1182/asheducation.V2000.1.69.69(Journal)
==========================================================

Created: 2019-10-10 05:10:03.0
ConfID: 5529586
CauseID: 1455911623
OtherID: 223320876
JT: Hematology
MD: Rosendaal, 2005 ,1,1,2005,Venous Thrombosis: The Role of Genes, Environment, and Behavior
DOI: 10.1182/asheducation-2005.1.1(Journal) (5529586-N )
DOI: 10.1182/asheducation.V2005.1.1.1(Journal)
==========================================================

Created: 2019-10-10 05:10:31.0
ConfID: 5529587
CauseID: 1455911760
OtherID: 693804731
JT: Hematology
MD: Gladwin, 2008 ,1,176,2008,Current and Future Therapies of Sickle Cell Anemia: An Historical Perspective
DOI: 10.1182/asheducation-2008.1.176(Journal) (5529587-N )
DOI: 10.1182/asheducation.V2008.1.176.0010176(Journal)
==========================================================

Created: 2019-10-10 06:09:46.0
ConfID: 5529588
CauseID: 1455915941
OtherID: 27712014, 1455915941
JT: Hematology
MD: Young, 2000 ,1,18,2000,New Insights into the Pathophysiology of Acquired Cytopenias
DOI: 10.1182/asheducation-2000.1.18(Journal) (5529588-N )
DOI: 10.1182/asheducation.V2000.1.18.18(Journal)
==========================================================

Created: 2019-10-10 05:14:13.0
ConfID: 5529589
CauseID: 1455912214
OtherID: 1455908303
JT: Hematology
MD: McCarthy, 2016 ,1,504,2016,Role of stem cell transplant and maintenance therapy in plasma cell disorders
DOI: 10.1182/asheducation-2016.1.504(Journal) (5529589-N )
DOI: 10.1182/asheducation.V2016.1.504.088352(Journal)
==========================================================

Created: 2019-10-10 05:14:50.0
ConfID: 5529590
CauseID: 1455912239
OtherID: 974344208
JT: Hematology
MD: Evans, 2009 ,1,273,2009,ASH evidence-based guidelines: statins in the prevention of venous thromboembolism
DOI: 10.1182/asheducation-2009.1.273(Journal) (5529590-N )
DOI: 10.1182/asheducation.V2009.1.273.0010273(Journal)
==========================================================

Created: 2019-10-10 08:32:40.0
ConfID: 5529596
CauseID: 1455924501
OtherID: 27712014, 1455924501
JT: Hematology
MD: Hedner, 2000 ,1,241,2000,Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia
DOI: 10.1182/asheducation-2000.1.241(Journal) (5529596-N )
DOI: 10.1182/asheducation.V2000.1.241.241(Journal)
==========================================================

Created: 2019-10-10 05:18:37.0
ConfID: 5529597
CauseID: 1455912441
OtherID: 1351047748
JT: Hematology
MD: Johnson, 2011 ,1,413,2011,Costs of Care in Hemophilia and Possible Implications of Health Care Reform
DOI: 10.1182/asheducation-2011.1.413(Journal) (5529597-N )
DOI: 10.1182/asheducation.V2011.1.413.3722509(Journal)
==========================================================

Created: 2019-10-10 06:01:51.0
ConfID: 5529598
CauseID: 1455915389
OtherID: 27712014, 1455915389
JT: Hematology
MD: Brittenham, 2000 ,1,39,2000,Clinical Consequences of New Insights in the Pathophysiology of Disorders of Iron and Heme Metabolism
DOI: 10.1182/asheducation-2000.1.39(Journal) (5529598-N )
DOI: 10.1182/asheducation.V2000.1.39.39(Journal)
==========================================================

Created: 2019-10-10 05:26:22.0
ConfID: 5529599
CauseID: 1455912836
OtherID: 299666112
JT: Hematology
MD: null, 2006 ,1,502,2006,Appendix A: Errata
DOI: 10.1182/asheducation-2006.1.502(Journal) (5529599-N )
DOI: 10.1182/asheducation-2006.1.502-a(Journal)
==========================================================

Created: 2019-10-10 05:26:28.0
ConfID: 5529601
CauseID: 1455912843
OtherID: 1455908922
JT: Hematology
MD: Ferrara, 2002 ,1,484,2002,Hematology Grants Workshop
DOI: 10.1182/asheducation-2002.1.484(Journal) (5529601-N )
DOI: 10.1182/asheducation.V2002.1.484.484(Journal)
==========================================================

Created: 2019-10-10 05:59:14.0
ConfID: 5529602
CauseID: 1455915210
OtherID: 27712014, 1455915210
JT: Hematology
MD: Felix, 2000 ,1,285,2000,Pediatric Acute Lymphoblastic Leukemia: Challenges and Controversies in 2000
DOI: 10.1182/asheducation-2000.1.285(Journal) (5529602-N )
DOI: 10.1182/asheducation.V2000.1.285.20000285(Journal)
==========================================================

Created: 2019-10-10 05:30:14.0
ConfID: 5529603
CauseID: 1455913158
OtherID: 1455912438
JT: Hematology
MD: Tubman, 2015 ,1,433,2015,Sickle solubility test to screen for sickle cell trait: what''s the harm?
DOI: 10.1182/asheducation-2015.1.433(Journal) (5529603-N )
DOI: 10.1182/asheducation.V2015.1.433.3919686(Journal)
==========================================================

Created: 2019-10-10 09:38:37.0
ConfID: 5529604
CauseID: 1455929501
OtherID: 27712014, 1455929501
JT: Hematology
MD: Kaushansky, 2000 ,1,438,2000,Glossary of Molecular Biology Terminology
DOI: 10.1182/asheducation-2000.1.438(Journal) (5529604-N )
DOI: 10.1182/asheducation.V2000.1.438.438(Journal)
==========================================================

Created: 2019-10-10 05:32:47.0
ConfID: 5529605
CauseID: 1455913593
OtherID: 1455912361
JT: Hematology
MD: Bernstein, 2009 ,1,532,2009,The incidence, natural history, biology, and treatment of transformed lymphomas
DOI: 10.1182/asheducation-2009.1.532(Journal) (5529605-N )
DOI: 10.1182/asheducation.V2009.1.532.532(Journal)
==========================================================

Created: 2019-10-10 05:34:49.0
ConfID: 5529607
CauseID: 1455913980
OtherID: 1374682252
JT: Hematology
MD: Richardson, 2014 ,1,255,2014,Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?
DOI: 10.1182/asheducation-2014.1.255(Journal) (5529607-N )
DOI: 10.1182/asheducation.V2014.1.255.3885263(Journal)
==========================================================

Created: 2019-10-10 05:36:13.0
ConfID: 5529616
CauseID: 1455914198
OtherID: 1455911939
JT: Hematology
MD: Haroche, 2015 ,1,571,2015,Uncommon histiocytic disorders: Rosai–Dorfman, juvenile xanthogranuloma, and Erdheim–Chester disease
DOI: 10.1182/asheducation-2015.1.571(Journal) (5529616-N )
DOI: 10.1182/asheducation.V2015.1.571.3916289(Journal)
==========================================================

Created: 2019-10-10 05:38:37.0
ConfID: 5529628
CauseID: 1455914312
OtherID: 1345441602
JT: Hematology
MD: Cuker, 2010 ,1,377,2010,Immune Thrombocytopenia
DOI: 10.1182/asheducation-2010.1.377(Journal) (5529628-N )
DOI: 10.1182/asheducation.V2010.1.377.3643150(Journal)
==========================================================

Created: 2019-10-10 05:38:54.0
ConfID: 5529650
CauseID: 1455914322
OtherID: 1455912671
JT: Hematology
MD: Pemmaraju, 2015 ,1,649,2015,Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs)
DOI: 10.1182/asheducation-2015.1.649(Journal) (5529650-N )
DOI: 10.1182/asheducation.V2015.1.649.3918650(Journal)
==========================================================

Created: 2019-10-10 05:43:02.0
ConfID: 5529675
CauseID: 1455914529
OtherID: 1374682252
JT: Hematology
MD: Flood, 2014 ,1,531,2014,New insights into genotype and phenotype of VWD
DOI: 10.1182/asheducation-2014.1.531(Journal) (5529675-N )
DOI: 10.1182/asheducation.V2014.1.531.3883265(Journal)
==========================================================

Created: 2019-10-10 07:32:39.0
ConfID: 5529686
CauseID: 1455919942
OtherID: 27712014, 1455919942
JT: Hematology
MD: Anderson, 2000 ,1,147,2000,Multiple Myeloma: New Insights and Therapeutic Approaches
DOI: 10.1182/asheducation-2000.1.147(Journal) (5529686-N )
DOI: 10.1182/asheducation.V2000.1.147.147(Journal)
==========================================================

Created: 2019-10-10 05:53:32.0
ConfID: 5529687
CauseID: 1455914963
OtherID: 1374682252
JT: Hematology
MD: Pabinger, 2014 ,1,410,2014,Flamethrowers: blood cells and cancer thrombosis risk
DOI: 10.1182/asheducation-2014.1.410(Journal) (5529687-N )
DOI: 10.1182/asheducation.V2014.1.410.3884864(Journal)
==========================================================

Created: 2019-10-10 05:57:32.0
ConfID: 5529688
CauseID: 1455915141
OtherID: 27712014, 1455915141
JT: Hematology
MD: Greiner, 2000 ,1,133,2000,Atypical Lymphoproliferative Diseases
DOI: 10.1182/asheducation-2000.1.133(Journal) (5529688-N )
DOI: 10.1182/asheducation.V2000.1.133.133(Journal)
==========================================================

Created: 2019-10-10 07:18:20.0
ConfID: 5529689
CauseID: 1455919008
OtherID: 27712014, 1455919008
JT: Hematology
MD: Rosse, 2000 ,1,2,2000,New Views of Sickle Cell Disease Pathophysiology and Treatment
DOI: 10.1182/asheducation-2000.1.2(Journal) (5529689-N )
DOI: 10.1182/asheducation.V2000.1.2.20000002(Journal)
==========================================================

Created: 2019-10-10 05:55:08.0
ConfID: 5529692
CauseID: 1455915055
OtherID: 299666112
JT: Hematology
MD: Mauro, 2006 ,1,219,2006,Defining and Managing Imatinib Resistance
DOI: 10.1182/asheducation-2006.1.219(Journal) (5529692-N )
DOI: 10.1182/asheducation.V2006.1.219.0010219(Journal)
==========================================================

Created: 2019-10-10 05:59:31.0
ConfID: 5529694
CauseID: 1455915217
OtherID: 1455913036
JT: Hematology
MD: Todd, 2000 ,1,424,2000,Hematology Grants Workshop—2000
DOI: 10.1182/asheducation.V2000.1.424.424(Journal) (5529694-N )
DOI: 10.1182/asheducation.V2000.1.424.20000424(Journal)
==========================================================

Created: 2019-10-10 06:05:30.0
ConfID: 5529695
CauseID: 1455915715
OtherID: 1396514514
JT: Hematology
MD: Cuker, 2015 ,1,117,2015,Monitoring and reversal of direct oral anticoagulants
DOI: 10.1182/asheducation-2015.1.117(Journal) (5529695-N )
DOI: 10.1182/asheducation.V2015.1.117.3916182(Journal)
==========================================================

Created: 2019-10-10 06:09:21.0
ConfID: 5529696
CauseID: 1455915922
OtherID: 1455914281
JT: Hematology
MD: null, 2012 ,1,667,2012,Arnason JE, Brown JR. Alemtuzumab use in relapsed and refractory chronic lymphocytic lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:119–120.
DOI: 10.1182/asheducation.V2012.1.667.bep667_667_667(Journal) (5529696-N )
DOI: 10.1182/asheducation.V2012.1.667(Journal)
==========================================================

Created: 2019-10-10 06:09:38.0
ConfID: 5529697
CauseID: 1455915932
OtherID: 1455911564
JT: Hematology
MD: Harrison, 2005 ,1,409,2005,Platelets and Thrombosis in Myeloproliferative Diseases
DOI: 10.1182/asheducation-2005.1.409(Journal) (5529697-N )
DOI: 10.1182/asheducation.V2005.1.409.409(Journal)
==========================================================

Created: 2019-10-10 06:18:54.0
ConfID: 5529698
CauseID: 1455916493
OtherID: 1455914280
JT: Hematology
MD: Dearden, 2015 ,1,361,2015,Management of prolymphocytic leukemia
DOI: 10.1182/asheducation-2015.1.361(Journal) (5529698-N )
DOI: 10.1182/asheducation.V2015.1.361.3917560(Journal)
==========================================================

Created: 2019-10-10 06:21:37.0
ConfID: 5529699
CauseID: 1455916642
OtherID: 1455915254
JT: Hematology
MD: Jaffe, 2009 ,1,523,2009,The 2008 WHO classification of lymphomas: implications for clinical practice and translational research
DOI: 10.1182/asheducation-2009.1.523(Journal) (5529699-N )
DOI: 10.1182/asheducation.V2009.1.523.0010523(Journal)
==========================================================

Created: 2019-10-10 06:24:26.0
ConfID: 5529700
CauseID: 1455916749
OtherID: 1455912330
JT: Hematology
MD: Reipert, 2014 ,1,372,2014,Risky business of inhibitors: HLA haplotypes, gene polymorphisms, and immune responses
DOI: 10.1182/asheducation-2014.1.372(Journal) (5529700-N )
DOI: 10.1182/asheducation.V2014.1.372.3884771(Journal)
==========================================================

Created: 2019-10-10 06:25:16.0
ConfID: 5529701
CauseID: 1455916772
OtherID: 1455912538
JT: Hematology
MD: Shah, 2010 ,1,310,2010,Evidence-Based Mini-Review: Treatment Options for Patients with Relapsed/Refractory Myeloma Previously Treated with Novel Agents and High-Dose Chemotherapy and Autologous Stem-Cell Transplantation
DOI: 10.1182/asheducation-2010.1.310(Journal) (5529701-N )
DOI: 10.1182/asheducation.V2010.1.310.3645859(Journal)
==========================================================

Created: 2019-10-10 06:29:42.0
ConfID: 5529702
CauseID: 1455916983
OtherID: 1455914209
JT: Hematology
MD: Grimwade, 2014 ,1,222,2014,Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?
DOI: 10.1182/asheducation-2014.1.222(Journal) (5529702-N )
DOI: 10.1182/asheducation.V2014.1.222.3884425(Journal)
==========================================================

Created: 2019-10-10 06:31:36.0
ConfID: 5529703
CauseID: 1455917063
OtherID: 1345441602
JT: Hematology
MD: Rosovsky, 2010 ,1,150,2010,Evidence-Based Mini-Review: Should All Patients with Idiopathic Venous Thromboembolic Events Be Screened Extensively for Occult Malignancy?
DOI: 10.1182/asheducation-2010.1.150(Journal) (5529703-N )
DOI: 10.1182/asheducation.V2010.1.150.3645826(Journal)
==========================================================

Created: 2019-10-10 09:20:19.0
ConfID: 5529704
CauseID: 1455928083
OtherID: 27712014, 1455928083
JT: Hematology
MD: Ansell, 2000 ,1,266,2000,Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism
DOI: 10.1182/asheducation-2000.1.266(Journal) (5529704-N )
DOI: 10.1182/asheducation.V2000.1.266.266(Journal)
==========================================================

Created: 2019-10-10 06:33:12.0
ConfID: 5529709
CauseID: 1455917131
OtherID: 1455908804
JT: Hematology
MD: Wang, 2003 ,1,1,2003,Ham-Wasserman Lecture
DOI: 10.1182/asheducation-2003.1.1(Journal) (5529709-N )
DOI: 10.1182/asheducation.V2003.1.1.1(Journal)
==========================================================

Created: 2019-10-10 06:33:23.0
ConfID: 5529710
CauseID: 1455917137
OtherID: 1455909130
JT: Hematology
MD: Shammo, 2016 ,1,552,2016,Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions
DOI: 10.1182/asheducation-2016.1.552(Journal) (5529710-N )
DOI: 10.1182/asheducation.V2016.1.552.088349(Journal)
==========================================================

Created: 2019-10-10 06:35:22.0
ConfID: 5529711
CauseID: 1455917210
OtherID: 1455913495
JT: Hematology
MD: Dinauer, 2000 ,1,303,2000,Inherited Neutrophil Disorders
DOI: 10.1182/asheducation.V2000.1.303.20000303(Journal) (5529711-N )
DOI: 10.1182/asheducation.V2000.1.303.303(Journal)
==========================================================

Created: 2019-10-10 06:35:26.0
ConfID: 5529712
CauseID: 1455917211
OtherID: 1455914776
JT: Hematology
MD: Brodsky, 2015 ,1,385,2015,Complement in hemolytic anemia
DOI: 10.1182/asheducation-2015.1.385(Journal) (5529712-N )
DOI: 10.1182/asheducation.V2015.1.385.3917876(Journal)
==========================================================

Created: 2019-10-10 06:38:32.0
ConfID: 5529714
CauseID: 1455917370
OtherID: 1455915206
JT: Hematology
MD: Linch, 2000 ,1,205,2000,Hodgkin''s Lymphoma
DOI: 10.1182/asheducation.V2000.1.205.20000205(Journal) (5529714-N )
DOI: 10.1182/asheducation.V2000.1.205.205(Journal)
==========================================================

Created: 2019-10-10 06:39:29.0
ConfID: 5529715
CauseID: 1455917402
OtherID: 1455908171
JT: Hematology
MD: Abla, 2015 ,1,565,2015,Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition
DOI: 10.1182/asheducation-2015.1.565(Journal) (5529715-N )
DOI: 10.1182/asheducation.V2015.1.565.3919688(Journal)
==========================================================

Created: 2019-10-10 06:41:19.0
ConfID: 5529716
CauseID: 1455917487
OtherID: 1455908791
JT: Hematology
MD: Macik, 2001 ,1,322,2001,Thrombophilia: What''s a Practitioner to Do?
DOI: 10.1182/asheducation-2001.1.322(Journal) (5529716-N )
DOI: 10.1182/asheducation.V2001.1.322.322(Journal)
==========================================================

Created: 2019-10-10 06:48:18.0
ConfID: 5529717
CauseID: 1455917734
OtherID: 1455916469
JT: Hematology
MD: Hellström-Lindberg, 2008 ,1,42,2008,Myelodysplastic Syndromes: An Historical Perspective
DOI: 10.1182/asheducation-2008.1.42(Journal) (5529717-N )
DOI: 10.1182/asheducation.V2008.1.42.0010042(Journal)
==========================================================

Created: 2019-10-10 06:48:28.0
ConfID: 5529718
CauseID: 1455917743
OtherID: 1351047748
JT: Hematology
MD: Cattaneo, 2011 ,1,70,2011,The Clinical Relevance of Response Variability to Antiplatelet Therapy
DOI: 10.1182/asheducation-2011.1.70(Journal) (5529718-N )
DOI: 10.1182/asheducation.V2011.1.70.3722478(Journal)
==========================================================

Created: 2019-10-10 06:49:13.0
ConfID: 5529719
CauseID: 1455917770
OtherID: 1455908640
JT: Hematology
MD: McCarthy, 2013 ,1,496,2013,Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients
DOI: 10.1182/asheducation-2013.1.496(Journal) (5529719-N )
DOI: 10.1182/asheducation.V2013.1.496.3847117(Journal)
==========================================================

Created: 2019-10-10 06:58:01.0
ConfID: 5529720
CauseID: 1455918115
OtherID: 1455912475
JT: Hematology
MD: Schimmer, 2005 ,1,215,2005,Targeting the IAP Family of Caspase Inhibitors as an Emerging Therapeutic Strategy
DOI: 10.1182/asheducation-2005.1.215(Journal) (5529720-N )
DOI: 10.1182/asheducation.V2005.1.215.215(Journal)
==========================================================

Created: 2019-10-10 06:59:38.0
ConfID: 5529721
CauseID: 1455918174
OtherID: 1455906861
JT: Hematology
MD: Hellström-Lindberg, 2000 ,1,110,2000,Achievements in Understanding and Treatment of Myelodysplastic Syndromes
DOI: 10.1182/asheducation.V2000.1.110.20000110(Journal) (5529721-N )
DOI: 10.1182/asheducation.V2000.1.110.110(Journal)
==========================================================

Created: 2019-10-10 07:15:48.0
ConfID: 5529722
CauseID: 1455918931
OtherID: 1455908941
JT: Hematology
MD: Kelly, 2015 ,1,514,2015,Hodgkin lymphoma in children and adolescents: improving the therapeutic index
DOI: 10.1182/asheducation-2015.1.514(Journal) (5529722-N )
DOI: 10.1182/asheducation.V2015.1.514.3917878(Journal)
==========================================================

Created: 2019-10-10 07:17:12.0
ConfID: 5529723
CauseID: 1455918976
OtherID: 1455908993
JT: Hematology
MD: Mahon, 2017 ,1,102,2017,Treatment-free remission in CML: who, how, and why?
DOI: 10.1182/asheducation-2017.1.102(Journal) (5529723-N )
DOI: 10.1182/asheducation.V2017.1.102.00014(Journal)
==========================================================

Created: 2019-10-10 07:19:21.0
ConfID: 5529724
CauseID: 1455919040
OtherID: 1455916819
JT: Hematology
MD: Hallek, 2005 ,1,285,2005,Chronic Lymphocytic Leukemia (CLL): First-Line Treatment
DOI: 10.1182/asheducation-2005.1.285(Journal) (5529724-N )
DOI: 10.1182/asheducation.V2005.1.285.0010285(Journal)
==========================================================

Created: 2019-10-10 07:35:48.0
ConfID: 5529725
CauseID: 1455920220
OtherID: 1455909223
JT: Hematology
MD: null, 2002 ,1,463,2002,Erratum
DOI: 10.1182/asheducation.V2002.1.463.0020463(Journal) (5529725-N )
DOI: 10.1182/asheducation.V2002.1.463.463(Journal)
==========================================================

Created: 2019-10-10 08:20:14.0
ConfID: 5529726
CauseID: 1455923603
OtherID: 1455914783
JT: Hematology
MD: Döhner, 2014 ,1,34,2014,Intermediate-risk acute myeloid leukemia therapy: current and future
DOI: 10.1182/asheducation-2014.1.34(Journal) (5529726-N )
DOI: 10.1182/asheducation.V2014.1.34.3882398(Journal)
==========================================================

Created: 2019-10-10 08:25:11.0
ConfID: 5529727
CauseID: 1455923955
OtherID: 1455913030
JT: Hematology
MD: de Leval, 2008 ,1,272,2008,Pathobiology and Molecular Profiling of Peripheral T-Cell Lymphomas
DOI: 10.1182/asheducation-2008.1.272(Journal) (5529727-N )
DOI: 10.1182/asheducation.V2008.1.272.0010272(Journal)
==========================================================

Created: 2019-10-10 08:32:22.0
ConfID: 5529730
CauseID: 1455924480
OtherID: 1455912896
JT: Hematology
MD: Ware, 2015 ,1,436,2015,Optimizing hydroxyurea therapy for sickle cell anemia
DOI: 10.1182/asheducation-2015.1.436(Journal) (5529730-N )
DOI: 10.1182/asheducation.V2015.1.436.3917688(Journal)
==========================================================

Created: 2019-10-10 08:39:15.0
ConfID: 5529731
CauseID: 1455924986
OtherID: 1455909453
JT: Hematology
MD: van Montfoort, 2014 ,1,60,2014,Recent insights into the role of the contact pathway in thrombo-inflammatory disorders
DOI: 10.1182/asheducation-2014.1.60(Journal) (5529731-N )
DOI: 10.1182/asheducation.V2014.1.60.3882400(Journal)
==========================================================

Created: 2019-10-10 08:45:44.0
ConfID: 5529732
CauseID: 1455925545
OtherID: 1455911363
JT: Hematology
MD: null, 2015 ,1,652,2015,Evens AM, Kostakoglu L. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. Hematology Am Soc Hematol Educ Program. 2014;2014:135-143.
DOI: 10.1182/asheducation-2015.1.652(Journal) (5529732-N )
DOI: 10.1182/asheducation.V2015.1.652.3918153(Journal)
==========================================================

Created: 2019-10-10 08:52:32.0
ConfID: 5529733
CauseID: 1455926020
OtherID: 1455923638
JT: Hematology
MD: Shanafelt, 2007 ,1,324,2007,Comprehensive Management of the CLL Patient: A Holistic Approach
DOI: 10.1182/asheducation-2007.1.324(Journal) (5529733-N )
DOI: 10.1182/asheducation.V2007.1.324.324(Journal)
==========================================================

Created: 2019-10-10 11:46:11.0
ConfID: 5529736
CauseID: 1455939829
OtherID: 1455920693
JT: Hematology
MD: Raphael, 2013 ,1,433,2013,Sickle cell disease pain management and the medical home
DOI: 10.1182/asheducation-2013.1.433(Journal) (5529736-N )
DOI: 10.1182/asheducation.V2013.1.433.3850724(Journal)
==========================================================

Created: 2019-10-10 12:22:47.0
ConfID: 5529739
CauseID: 1455942350
OtherID: 1455916471
JT: Hematology
MD: Kobos, 2015 ,1,522,2015,Advances in therapies for non-Hodgkin lymphoma in children
DOI: 10.1182/asheducation-2015.1.522(Journal) (5529739-N )
DOI: 10.1182/asheducation.V2015.1.522.3916185(Journal)
==========================================================

Created: 2019-10-10 12:28:36.0
ConfID: 5529740
CauseID: 1455942730
OtherID: 1455916085
JT: Hematology
MD: Cabanillas, 2000 ,1,166,2000,Managing Indolent Lymphomas in Relapse
DOI: 10.1182/asheducation.V2000.1.166.20000166(Journal) (5529740-N )
DOI: 10.1182/asheducation.V2000.1.166.166(Journal)
==========================================================

Created: 2020-04-19 05:13:06.0
ConfID: 5588560
CauseID: 1467744309
OtherID: 27712014
JT: Hematology
MD: Sachs, 2000 ,1,1,2000,The Molecular Control of Hematopoiesis and Leukemia: From Basic Biology to the Clinic
DOI: 10.1182/asheducation-2000.1.1(Journal) (5588560-N )
DOI: 10.1182/asheducation.V2000.1.1.1(Journal)
==========================================================

Created: 2022-12-09 11:07:55.0
ConfID: 6683526
CauseID: 1553803279
OtherID: 1553803274
JT: Hematology
MD: O''Dwyer, 2022 ,1,197,2022,Optimal approach to T-cell ALL
DOI: 10.1182/hematology.2022000337C(Journal) (6683526-N )
DOI: 10.1182/hematology.2022000337(Journal)